Tim-3 as a target for cancer immunotherapy and mechanisms of action

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Du, Wenwen ^a,b   Yang, Min ^b,c   Turner, Abbey ^b   Xu, Chunling ^d   Ferris, Robert L ^b   Huang, Jianan ^a   Kane, Lawrence P ^b   Lu, Binfeng ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SOOCHOW UNIVERSITY   (China)

^d THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Antitumor immune responses; T cell subsets; TIM 3; Tumor microenvironment

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; HAVCR2 PROTEIN, HUMAN; LIGAND;

ALLOIMMUNITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION; INNATE IMMUNITY; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LIGANDS; NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 85015730293     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030645     Document Type: Review

References (94)

1. Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723. [CrossRef] [PubMed]
2. Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364, 2517–2526. [CrossRef] [PubMed]
3. Maio, M.; Grob, J.J.; Aamdal, S.; Bondarenko, I.; Robert, C.; Thomas, L.; Garbe, C.; Chiarion-Sileni, V.; Testori, A.; Chen, T.T.; et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 2015, 33, 1191–1196. [CrossRef] [PubMed]
4. Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Patt, D.; Chen, T.T.; Berman, D.M.; Wolchok, J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015, 33, 1889–1894. [CrossRef] [PubMed]
5. Selby, M.J.; Engelhardt, J.J.; Quigley, M.; Henning, K.A.; Chen, T.; Srinivasan, M.; Korman, A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013, 1, 32–42. [CrossRef] [PubMed]
6. Romano, E.; Kusio-Kobialka, M.; Foukas, P.G.; Baumgaertner, P.; Meyer, C.; Ballabeni, P.; Michielin, O.; Weide, B.; Romero, P.; Speiser, D.E. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl. Acad. Sci. USA 2015, 112, 6140–6145. [CrossRef] [PubMed]
7. Dong, H.; Zhu, G.; Tamada, K.; Chen, L. B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5, 1365–1369. [PubMed]
8. Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192, 1027–1034. [CrossRef] [PubMed]
9. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [CrossRef] [PubMed]
10. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [CrossRef] [PubMed]
11. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369, 122–133. [CrossRef] [PubMed]
12. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [CrossRef] [PubMed]
13. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372, 2521–2532. [CrossRef] [PubMed]
14. Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 2018–2028. [CrossRef] [PubMed]
15. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373, 23–34. [CrossRef] [PubMed]
16. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372, 2509–2520. [CrossRef] [PubMed]
17. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crino, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 123–135. [CrossRef] [PubMed]
18. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813. [CrossRef] [PubMed]
19. Anderson, A.C.; Anderson, D.E.; Bregoli, L.; Hastings, W.D.; Kassam, N.; Lei, C.; Chandwaskar, R.; Karman, J.; Su, E.W.; Hirashima, M.; et al. Promotion of tissue inflammation by the immune receptor TIM-3 expressed on innate immune cells. Science 2007, 318, 1141–1143. [CrossRef] [PubMed]
20. + T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 2009, 39, 2492–2501. [CrossRef] [PubMed]
21. Monney, L.; Sabatos, C.A.; Gaglia, J.L.; Ryu, A.; Waldner, H.; Chernova, T.; Manning, S.; Greenfield, E.A.; Coyle, A.J.; Sobel, R.A.; et al. Th1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415, 536–541. [CrossRef] [PubMed]
22. Zhu, C.; Anderson, A.C.; Schubart, A.; Xiong, H.; Imitola, J.; Khoury, S.J.; Zheng, X.X.; Strom, T.B.; Kuchroo, V.K. The TIM-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6, 1245–1252. [CrossRef] [PubMed]
23. Sabatos, C.A.; Chakravarti, S.; Cha, E.; Schubart, A.; Sanchez-Fueyo, A.; Zheng, X.X.; Coyle, A.J.; Strom, T.B.; Freeman, G.J.; Kuchroo, V.K. Interaction of TIM-3 and TIM-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003, 4, 1102–1110. [CrossRef] [PubMed]
24. Sanchez-Fueyo, A.; Tian, J.; Picarella, D.; Domenig, C.; Zheng, X.X.; Sabatos, C.A.; Manlongat, N.; Bender, O.; Kamradt, T.; Kuchroo, V.K.; et al. TIM-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003, 4, 1093–1101. [CrossRef] [PubMed]
25. Jones, R.B.; Ndhlovu, L.C.; Barbour, J.D.; Sheth, P.M.; Jha, A.R.; Long, B.R.; Wong, J.C.; Satkunarajah, M.; Schweneker, M.; Chapman, J.M.; et al. TIM-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205, 2763–2779. [CrossRef] [PubMed]
26. Hafler, D.A.; Kuchroo, V. TIMs: Central regulators of immune responses. J. Exp. Med. 2008, 205, 2699–2701. [CrossRef] [PubMed]
27. + T cells. J. Virol. 2009, 83, 9122–9130. [CrossRef] [PubMed]
28. + T cells by rapid induction of multiple inhibitory receptors. J. Immunol. 2010, 184, 4696–4707. [CrossRef] [PubMed]
29. + T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207, 2175–2186. [CrossRef] [PubMed]
30. Sakuishi, K.; Jayaraman, P.; Behar, S.M.; Anderson, A.C.; Kuchroo, V.K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011, 32, 345–349. [CrossRef] [PubMed]
31. Koyama, S.; Akbay, E.A.; Li, Y.Y.; Herter-Sprie, G.S.; Buczkowski, K.A.; Richards, W.G.; Gandhi, L.; Redig, A.J.; Rodig, S.J.; Asahina, H.; et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016, 7, 10501. [CrossRef] [PubMed]
32. Liu, J.; Zhang, S.; Hu, Y.; Yang, Z.; Li, J.; Liu, X.; Deng, L.; Wang, Y.; Zhang, X.; Jiang, T.; Lu, X. Targeting PD-1 and TIM-3 pathways to reverse CD8 T cell exhaustion and enhance ex vivo T cell responses to autologous dendritic/tumor vaccines. J. Immunother. 2016, 39, 171–180. [CrossRef] [PubMed]
33. Gorman, J.V.; Starbeck-Miller, G.; Pham, N.L.; Traver, G.L.; Rothman, P.B.; Harty, J.T.; Colgan, J.D. TIM-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J. Immunol. 2014, 192, 3133–3142. [CrossRef] [PubMed]
34. Cao, E.; Zang, X.; Ramagopal, U.A.; Mukhopadhaya, A.; Fedorov, A.; Fedorov, E.; Zencheck, W.D.; Lary, J.W.; Cole, J.L.; Deng, H.; et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 2007, 26, 311–321. [CrossRef] [PubMed]
35. Anderson, A.C.; Xiao, S.; Kuchroo, V.K. TIM protein structures reveal a unique face for ligand binding. Immunity 2007, 26, 273–275. [CrossRef] [PubMed]
36. Lee, J.; Su, E.W.; Zhu, C.; Hainline, S.; Phuah, J.; Moroco, J.A.; Smithgall, T.E.; Kuchroo, V.K.; Kane, L.P. Phosphotyrosine-dependent coupling of TIM-3 to T cell receptor signaling pathways. Mol. Cell Biol. 2011, 31, 3963–3974. [CrossRef] [PubMed]
37. Ferris, R.L.; Lu, B.; Kane, L.P. Too much of a good thing? TIM-3 and TCR signaling in T cell exhaustion. J. Immunol. 2014, 193, 1525–1530. [CrossRef] [PubMed]
38. Kane, L.P. Antigen receptor kinase two-step. J. Immunol. 2014, 193, 4277–4278. [CrossRef] [PubMed]
39. Phong, B.L.; Avery, L.; Sumpter, T.L.; Gorman, J.V.; Watkins, S.C.; Colgan, J.D.; Kane, L.P. TIM-3 enhances FcεRI-proximal signaling to modulate mast cell activation. J. Exp. Med. 2015, 212, 2289–2304. [CrossRef] [PubMed]
40. Santiago, C.; Ballesteros, A.; Tami, C.; Martinez-Munoz, L.; Kaplan, G.G.; Casasnovas, J.M. Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity 2007, 26, 299–310. [CrossRef] [PubMed]
41. Anderson, A.C.; Joller, N.; Kuchroo, V.K. Lag-3, TIM-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016, 44, 989–1004. [CrossRef] [PubMed]
42. DeKruyff, R.H.; Bu, X.; Ballesteros, A.; Santiago, C.; Chim, Y.L.; Lee, H.H.; Karisola, P.; Pichavant, M.; Kaplan, G.G.; Umetsu, D.T.; et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 2010, 184, 1918–1930. [CrossRef] [PubMed]
43. Nakayama, M.; Akiba, H.; Takeda, K.; Kojima, Y.; Hashiguchi, M.; Azuma, M.; Yagita, H.; Okumura, K. TIM-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009, 113, 3821–3830. [CrossRef] [PubMed]
44. Tang, D.; Lotze, M.T. Tumor immunity times out: TIM-3 and HMGB1. Nat. Immunol. 2012, 13, 808–810. [CrossRef] [PubMed]
45. Huang, Y.H.; Zhu, C.; Kondo, Y.; Anderson, A.C.; Gandhi, A.; Russell, A.; Dougan, S.K.; Petersen, B.S.; Melum, E.; Pertel, T.; et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517, 386–390. [CrossRef] [PubMed]
46. Van de Weyer, P.S.; Muehlfeit, M.; Klose, C.; Bonventre, J.V.; Walz, G.; Kuehn, E.W. A highly conserved tyrosine of TIM-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem. Biophys. Res. Commun. 2006, 351, 571–576. [CrossRef] [PubMed]
47. Clayton, K.L.; Haaland, M.S.; Douglas-Vail, M.B.; Mujib, S.; Chew, G.M.; Ndhlovu, L.C.; Ostrowski, M.A. T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J. Immunol. 2014, 192, 782–791. [CrossRef] [PubMed]
48. Tomkowicz, B.; Walsh, E.; Cotty, A.; Verona, R.; Sabins, N.; Kaplan, F.; Santulli-Marotto, S.; Chin, C.N.; Mooney, J.; Lingham, R.B.; et al. TIM-3 suppresses anti-CD3/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway. PLoS ONE 2015, 10, e0140694. [CrossRef] [PubMed]
49. Rangachari, M.; Zhu, C.; Sakuishi, K.; Xiao, S.; Karman, J.; Chen, A.; Angin, M.; Wakeham, A.; Greenfield, E.A.; Sobel, R.A.; et al. Bat3 promotes T cell responses and autoimmunity by repressing TIM-3-mediated cell death and exhaustion. Nat. Med. 2012, 18, 1394–1400. [CrossRef] [PubMed]
50. Yang, L.; Anderson, D.E.; Kuchroo, J.; Hafler, D.A. Lack of TIM-3 immunoregulation in multiple sclerosis. J. Immunol. 2008, 180, 4409–4414. [CrossRef] [PubMed]
51. Boenisch, O.; D’Addio, F.; Watanabe, T.; Elyaman, W.; Magee, C.N.; Yeung, M.Y.; Padera, R.F.; Rodig, S.J.; Murayama, T.; Tanaka, K.; et al. TIM-3: A novel regulatory molecule of alloimmune activation. J. Immunol. 2010, 185, 5806–5819. [CrossRef] [PubMed]
52. Veenstra, R.G.; Taylor, P.A.; Zhou, Q.; Panoskaltsis-Mortari, A.; Hirashima, M.; Flynn, R.; Liu, D.; Anderson, A.C.; Strom, T.B.; Kuchroo, V.K.; et al. Contrasting acute graft-versus-host disease effects of TIM-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 2012, 120, 682–690. [CrossRef] [PubMed]
53. + T cells in metastases from melanoma patients. J. Clin. Investig. 2011, 121, 2350–2360. [CrossRef] [PubMed]
54. Gao, X.; Zhu, Y.; Li, G.; Huang, H.; Zhang, G.; Wang, F.; Sun, J.; Yang, Q.; Zhang, X.; Lu, B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 2012, 7, e30676. [CrossRef] [PubMed]
55. Yan, J.; Zhang, Y.; Zhang, J.P.; Liang, J.; Li, L.; Zheng, L. TIM-3 expression defines regulatory T cells in human tumors. PLoS ONE 2013, 8, e58006. [CrossRef] [PubMed]
56. + tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2015, 31, 808–811. [PubMed]
57. Thommen, D.S.; Schreiner, J.; Muller, P.; Herzig, P.; Roller, A.; Belousov, A.; Umana, P.; Pisa, P.; Klein, C.; Bacac, M.; et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol. Res. 2015, 3, 1344–1355. [CrossRef] [PubMed]
58. Jie, H.B.; Gildener-Leapman, N.; Li, J.; Srivastava, R.M.; Gibson, S.P.; Whiteside, T.L.; Ferris, R.L. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br. J. Cancer 2013, 109, 2629–2635. [CrossRef] [PubMed]
59. Cai, C.; Xu, Y.F.; Wu, Z.J.; Dong, Q.; Li, M.Y.; Olson, J.C.; Rabinowitz, Y.M.; Wang, L.H.; Sun, Y. TIM-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J. Urol. 2016, 34, 561–567. [CrossRef] [PubMed]
60. Cheng, G.; Li, M.; Wu, J.; Ji, M.; Fang, C.; Shi, H.; Zhu, D.; Chen, L.; Zhao, J.; Shi, L.; et al. Expression of TIM-3 in gastric cancer tissue and its relationship with prognosis. Int. J. Clin. Exp. Pathol. 2015, 8, 9452–9457. [PubMed]
61. Jinhua, X.; Ji, W.; Shouliang, C.; Liangfeng, Z.; Feiyue, J.; Lin, Y.; Yan, Z.; Haoming, J. Expression of immune checkpoints in T cells of esophageal cancer patients. Oncotarget 2016, 7, 63669–63678. [CrossRef] [PubMed]
62. + T cells in prostate cancer patients correlates with CD38 and TIM-3 expression. Cancer Immunol. Immunother. 2015, 64, 1487–1494. [CrossRef] [PubMed]
63. Yang, Z.Z.; Grote, D.M.; Ziesmer, S.C.; Niki, T.; Hirashima, M.; Novak, A.J.; Witzig, T.E.; Ansell, S.M. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Investig. 2012, 122, 1271–1282. [CrossRef] [PubMed]
64. Sakuishi, K.; Apetoh, L.; Sullivan, J.M.; Blazar, B.R.; Kuchroo, V.K.; Anderson, A.C. Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207, 2187–2194. [CrossRef] [PubMed]
65. Ngiow, S.F.; von Scheidt, B.; Akiba, H.; Yagita, H.; Teng, M.W.; Smyth, M.J. Anti-TIM-3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71, 3540–3551. [CrossRef] [PubMed]
66. Panduro, M.; Benoist, C.; Mathis, D. Tissue Tregs. Annu. Rev. Immunol. 2016, 34, 609–633. [CrossRef] [PubMed]
67. + Tregs. J. Clin. Investig. 2012, 122, 2395–2404. [CrossRef] [PubMed]
68. Schiering, C.; Krausgruber, T.; Chomka, A.; Frohlich, A.; Adelmann, K.; Wohlfert, E.A.; Pott, J.; Griseri, T.; Bollrath, J.; Hegazy, A.N.; et al. The alarmin IL-33 promotes regulatory T cell function in the intestine. Nature 2014, 513, 564–568. [CrossRef] [PubMed]
69. Burzyn, D.; Kuswanto, W.; Kolodin, D.; Shadrach, J.L.; Cerletti, M.; Jang, Y.; Sefik, E.; Tan, T.G.; Wagers, A.J.; Benoist, C.; et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013, 155, 1282–1295. [CrossRef] [PubMed]
70. Odegaard, J.I.; Lee, M.W.; Sogawa, Y.; Bertholet, A.M.; Locksley, R.M.; Weinberg, D.E.; Kirichok, Y.; Deo, R.C.; Chawla, A. Perinatal licensing of thermogenesis by IL-33 and ST2. Cell 2016, 166, 841–854. [CrossRef] [PubMed]
71. Ndhlovu, L.C.; Lopez-Verges, S.; Barbour, J.D.; Jones, R.B.; Jha, A.R.; Long, B.R.; Schoeffler, E.C.; Fujita, T.; Nixon, D.F.; Lanier, L.L. TIM-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012, 119, 3734–3743. [CrossRef] [PubMed]
72. Ju, Y.; Hou, N.; Meng, J.; Wang, X.; Zhang, X.; Zhao, D.; Liu, Y.; Zhu, F.; Zhang, L.; Sun, W.; et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 2010, 52, 322–329. [CrossRef] [PubMed]
73. Hou, H.; Liu, W.; Wu, S.; Lu, Y.; Peng, J.; Zhu, Y.; Wang, F.; Sun, Z. TIM-3 negatively mediates natural killer cell function in LPS-induced endotoxic shock. PLoS ONE 2014, 9, e110585. [CrossRef] [PubMed]
74. Gallois, A.; Silva, I.; Osman, I.; Bhardwaj, N. Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology 2014, 3, e946365. [CrossRef] [PubMed]
75. Tripathi, S.; Chabtini, L.; Dakle, P.J.; Smith, B.; Akiba, H.; Yagita, H.; Guleria, I. Effect of TIM-3 blockade on the immunophenotype and cytokine profile of murine uterine NK cells. PLoS ONE 2015, 10, e0123439. [CrossRef] [PubMed]
76. Da Silva, I.P.; Gallois, A.; Jimenez-Baranda, S.; Khan, S.; Anderson, A.C.; Kuchroo, V.K.; Osman, I.; Bhardwaj, N. Reversal of NK cell exhaustion in advanced melanoma by TIM-3 blockade. Cancer Immunol. Res. 2014, 2, 410–422. [CrossRef] [PubMed]
77. Gleason, M.K.; Lenvik, T.R.; McCullar, V.; Felices, M.; O’Brien, M.S.; Cooley, S.A.; Verneris, M.R.; Cichocki, F.; Holman, C.J.; Panoskaltsis-Mortari, A.; et al. TIM-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012, 119, 3064–3072. [CrossRef] [PubMed]
78. Han, G.; Chen, G.; Shen, B.; Li, Y. TIM-3: An activation marker and activation limiter of innate immune cells. Front. Immunol. 2013, 4, 449. [CrossRef] [PubMed]
79. Dai, S.Y.; Nakagawa, R.; Itoh, A.; Murakami, H.; Kashio, Y.; Abe, H.; Katoh, S.; Kontani, K.; Kihara, M.; Zhang, S.L.; et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. Immunol. 2005, 175, 2974–2981. [CrossRef] [PubMed]
80. Maurya, N.; Gujar, R.; Gupta, M.; Yadav, V.; Verma, S.; Sen, P. Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton’s tyrosine kinase and c-Src. J. Immunol. 2014, 193, 3417–3425. [CrossRef] [PubMed]
81. Chiba, S.; Baghdadi, M.; Akiba, H.; Yoshiyama, H.; Kinoshita, I.; Dosaka-Akita, H.; Fujioka, Y.; Ohba, Y.; Gorman, J.V.; Colgan, J.D.; et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012, 13, 832–842. [CrossRef] [PubMed]
82. Yang, X.; Jiang, X.; Chen, G.; Xiao, Y.; Geng, S.; Kang, C.; Zhou, T.; Li, Y.; Guo, X.; Xiao, H.; et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J. Immunol. 2013, 190, 2068–2079. [CrossRef] [PubMed]
83. + monocytes. J. Leukoc. Biol. 2012, 91, 189–196. [CrossRef] [PubMed]
84. Zhang, Y.; Ma, C.J.; Wang, J.M.; Ji, X.J.; Wu, X.Y.; Jia, Z.S.; Moorman, J.P.; Yao, Z.Q. TIM-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS ONE 2011, 6, e19664. [CrossRef] [PubMed]
85. Sada-Ovalle, I.; Chavez-Galan, L.; Torre-Bouscoulet, L.; Nava-Gamino, L.; Barrera, L.; Jayaraman, P.; Torres-Rojas, M.; Salazar-Lezama, M.A.; Behar, S.M. The TIM-3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J. Immunol. 2012, 189, 5896–5902. [CrossRef] [PubMed]
86. Jayaraman, P.; Sada-Ovalle, I.; Nishimura, T.; Anderson, A.C.; Kuchroo, V.K.; Remold, H.G.; Behar, S.M. IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J. Immunol. 2013, 190, 4196–4204. [CrossRef] [PubMed]
87. Jayaraman, P.; Sada-Ovalle, I.; Beladi, S.; Anderson, A.C.; Dardalhon, V.; Hotta, C.; Kuchroo, V.K.; Behar, S.M. TIM-3 binding to galectin-9 stimulates antimicrobial immunity. J. Exp. Med. 2010, 207, 2343–2354. [CrossRef] [PubMed]
88. Ocana-Guzman, R.; Torre-Bouscoulet, L.; Sada-Ovalle, I. TIM-3 regulates distinct functions in macrophages. Front. Immunol. 2016, 7, 229. [CrossRef] [PubMed]
89. Dannenmann, S.R.; Thielicke, J.; Stockli, M.; Matter, C.; von Boehmer, L.; Cecconi, V.; Hermanns, T.; Hefermehl, L.; Schraml, P.; Moch, H.; et al. Tumor-associated macrophages subvert T cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013, 2, e23562. [CrossRef] [PubMed]
90. Flecken, T.; Sarobe, P. TIM-3 expression in tumour-associated macrophages: A new player in HCC progression. Gut 2015, 64, 1502–1503. [CrossRef] [PubMed]
91. + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int. Immunopharmacol. 2016, 34, 101–106. [CrossRef] [PubMed]
92. Li, J.; Cao, D.; Guo, G.; Wu, Y.; Chen, Y. Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma. J. Mol. Histol. 2013, 44, 213–220. [CrossRef] [PubMed]
93. Yan, W.; Liu, X.; Ma, H.; Zhang, H.; Song, X.; Gao, L.; Liang, X.; Ma, C. TIM-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut 2015, 64, 1593–1604. [CrossRef] [PubMed]
94. + myeloid cells. J. Immunol. 2010, 185, 1383–1392. [CrossRef] [PubMed]